已发表论文

高 Tiam1 表达可预测恶性实体瘤患者的淋巴转移阳性和较低的生存率:系统评价和荟萃分析

 

Authors Yang C, Ma C, Li Y, Mo P, Yang Y

Received 20 October 2018

Accepted for publication 10 May 2019

Published 25 July 2019 Volume 2019:12 Pages 5925—5936

DOI https://doi.org/10.2147/OTT.S191571

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Ms Justinn Cochran

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Geoffrey Pietersz

Background: Many studies have explored the prognostic value of T-cell lymphoma invasion and metastasis inducing factor 1 (Tiam1) and its association with lymphatic metastasis in malignant solid tumors, but the conclusions remain controversial. Therefore, we performed a meta-analysis to systematically assess the prognostic value of Tiam1 expression and its association with lymphatic metastasis in malignant solid tumors.
Methods: We searched eligible studies in PubMed, Web of Science and EMBASE databases (from inception up to October 2018). The combined HR with 95% CI was used to estimate the prognostic value of Tiam1 expression. The correlation between Tiam1 expression and lymphatic metastasis was assessed using the combined odds ratio (OR) with 95% CI.
Results: A total of 17 studies with 2,228 patients with solid tumors were included in this meta-analysis. The overall estimated results showed that high Tiam1 expression was significantly associated with shorter overall survival (HR= 2.08, 95% CI: 1.62–2.68, <0.01), and disease-free survival (HR = 1.86, 95% CI: 1.49–2.32, <0.01). Besides, we also found that there was a close relationship between high Tiam1 expression and positive lymphatic metastasis (OR=2.63; 95% CI: 1.79–3.84, <0.01).
Conclusion: High Tiam1 expression was significantly associated with shorter survival and positive lymphatic metastasis in patients with malignant solid tumors. Therefore, Tiam1 may be a promising prognostic biomarker and an effective therapeutic target for malignant solid tumors.
Keywords: tumor, Tiam1, survival, meta-analysis




Figure 1 Flow diagram of selecting eligible studies.